ARTICLE | Finance
Esperion's LDL-C hangover
Why Esperion fell again on FDA's lack of committal to LDL-C
July 11, 2016 7:00 AM UTC
The fall of Esperion Therapeutics Inc. (NASDAQ:ESPR) continued last month as FDA's refusal to commit to LDL-C lowering as an approvable surrogate endpoint for the company's statin alternative has seen the biotech lose 90% of its value in the past year.
On June 28, Esperion fell $4.40 (27%) to $11.78 after it said FDA "did not provide clarity on a regulatory pathway" about upcoming Phase III trials for bempedoic acid (ETC-1002) in statin-intolerant patients in which the company wants to use LDL-C lowering as a surrogate endpoint. ...